Evidence map›Paper›PMID 28973134›Full record

ArticleEndocrinology2017

MEF2C Interacts With c-FOS in PTH-Stimulated Mmp13 Gene Expression in Osteoblastic Cells.

Teruyo Nakatani, Nicola C Partridge

Open access · bronzeAbstract read
In one paragraph

Article in Endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Abaloparatide at the Same Dose Has the Same Effects on Bone as PTH (1-34) in Mice.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2020
    Article
  11. Review
  12. Article
  13. The Deletion of Hdac4 in Mouse Osteoblasts Influences Both Catabolic and Anabolic Effects in Bone.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Teruyo NakataniDepartment of Basic Science and Craniofacial Biology, New York University College of Dentistry, New York, New York 10010.
Nicola C PartridgeDepartment of Basic Science and Craniofacial Biology, New York University College of Dentistry, New York, New York 10010.
New York University · US

Funding

Nuclear Events in PTHR1 Action on BoneR01DK047420 · NIDDK · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Nicola C Partridge · 1994 to 2026
$8.0M
Nuclear Events in PTHR1 Action on BoneR56DK047420 · NIDDK · NEW YORK UNIVERSITY · PI PARTRIDGE, NICOLA C · 2010 to 2021
$548k
NIDDK NIH HHS R01 DK047420NIDDK NIH HHS R56 DK047420
6 · The paper itself

Abstract

Parathyroid hormone (PTH) regulates the transcription of many genes in the osteoblast. One of these genes is Mmp13, which is involved in bone remodeling and early stages of endochondral bone formation. Previously, we reported that PTH induces Mmp13 transcription by regulating the dissociation of histone deacetylase 4 (HDAC4) from runt-related transcription factor 2 (Runx2), and the association of the HATs, p300, and p300/CREB binding protein (CBP)-associated factor. It is known that, in addition to Runx2, HDAC4 binds to the transcription factor, myocyte-specific enhancer factor 2c (MEF2C), and represses its activity. In this work, we investigated whether MEF2C participates in PTH-stimulated Mmp13 gene expression in osteoblastic cells and how it does so. Knockdown of Mef2c in UMR 106-01 cells repressed Mmp13 messenger RNA expression and promoter activity with or without PTH treatment. Chromatin immunoprecipitation (ChIP) assays showed that MEF2C associated with the Mmp13 promoter; this increased after 4 hours of PTH treatment. ChIP-reChIP results indicate that endogenous MEF2C associates with HDAC4 on the Mmp13 promoter; after PTH treatment, this association decreased. From gel shift, ChIP, and promoter-reporter assays, MEF2C was found to associate with the activator protein-1 (AP-1) site without directly binding to DNA and had its stimulatory effect through interaction with c-FOS. In conclusion, MEF2C is necessary for Mmp13 gene expression at the transcriptional level and participates in PTH-stimulated Mmp13 gene expression by increased binding to c-FOS at the AP-1 site in the Mmp13 promoter. The observation of MEF2C interacting with a member of the AP-1 transcription factor family provides knowledge of the functions of HDAC4, c-FOS, and MEF2C.

Indexed as

AnimalsAnimals, NewbornCells, CulturedGene Expression Regulation, EnzymologicMatrix Metalloproteinase 13MEF2 Transcription FactorsOsteoblastsParathyroid HormonePromoter Regions, GeneticProtein BindingProto-Oncogene Proteins c-fosRatsTranscription, GeneticMatrix Metalloproteinase 13Mef2c protein, mouseMEF2 Transcription FactorsMmp13 protein, mouseParathyroid HormoneProto-Oncogene Proteins c-fos

Identifiers

PMID28973134
PMCPMC5695834
OpenAlexW2739066978

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.